NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

被引：1
|
作者：
Tucker, Helen [1 ]
Umeweni, Nwamaka [1 ]
Robertson, Janet [1 ]
Adam, Jane [1 ]
机构：
[1] Natl Inst Hlth & Care Excellence, London SW1A 2BU, England
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 13期
关键词：
OPEN-LABEL; PHASE-3;
D O I：
10.1016/S1470-2045(14)71033-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1425 / 1426
页数：2
相关论文
共 50 条
  • [1] Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Boland, Angela
    Dickson, Rumona
    Dwan, Kerry
    Richardson, Marty
    Dundar, Yenal
    Davis, Helen
    Banks, Lindsay
    [J]. PHARMACOECONOMICS, 2015, 33 (09) : 893 - 904
  • [2] Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Angela Boland
    Rumona Dickson
    Kerry Dwan
    Marty Richardson
    Yenal Dundar
    Helen Davis
    Lindsay Banks
    [J]. PharmacoEconomics, 2015, 33 : 893 - 904
  • [3] NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
    Perampaladas, Kumar
    Hay, Nicola
    Rinaldi, Fiona
    Robertson, Janet
    Adam, Jane
    [J]. LANCET ONCOLOGY, 2013, 14 (01): : 21 - 22
  • [4] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Delea, Thomas E.
    Amdahl, Jordan
    Wang, Alice
    Amonkar, Mayur M.
    Thabane, Marroon
    [J]. PHARMACOECONOMICS, 2015, 33 (04) : 367 - 380
  • [5] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Thomas E. Delea
    Jordan Amdahl
    Alice Wang
    Mayur M. Amonkar
    Marroon Thabane
    [J]. PharmacoEconomics, 2015, 33 : 367 - 380
  • [6] Implementation of a National Plan in Argentina to Detect Braf V600 Mutation-Positive Metastatic Melanoma
    Latorre, M. C.
    Gutierrez, M.
    Garcia-Rivello, H. J.
    Livellaro, B.
    Lozano, G. C.
    Maldonado, C.
    Volonteri, V. I.
    De La Iglesia, P.
    Aylagas, D.
    Garritano, G.
    Carrizo, M.
    Mocetti, E. M.
    Moffa, F.
    [J]. MODERN PATHOLOGY, 2014, 27 : 136A - 136A
  • [7] Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
    Beale, Sophie
    Dickson, Rumona
    Bagust, Adrian
    Blundell, Michaela
    Dundar, Yenal
    Boland, Angela
    Marshall, Ernie
    Plummer, Ruth
    Proudlove, Chris
    [J]. PHARMACOECONOMICS, 2013, 31 (12) : 1121 - 1129
  • [8] Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
    Sophie Beale
    Rumona Dickson
    Adrian Bagust
    Michaela Blundell
    Yenal Dundar
    Angela Boland
    Ernie Marshall
    Ruth Plummer
    Chris Proudlove
    [J]. PharmacoEconomics, 2013, 31 : 1121 - 1129
  • [9] Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Rachel Houten
    Janette Greenhalgh
    James Mahon
    Sarah Nevitt
    Sophie Beale
    Angela Boland
    Tosin Lambe
    Yenal Dundar
    Eleanor Kotas
    Joanne McEntee
    [J]. PharmacoEconomics - Open, 2021, 5 : 13 - 22
  • [10] Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Houten, Rachel
    Greenhalgh, Janette
    Mahon, James
    Nevitt, Sarah
    Beale, Sophie
    Boland, Angela
    Lambe, Tosin
    Dundar, Yenal
    Kotas, Eleanor
    McEntee, Joanne
    [J]. PHARMACOECONOMICS-OPEN, 2021, 5 (01) : 13 - 22
12345